跳至主要内容
临床试验/NCT00234897
NCT00234897已完成4 期

Humira Efficacy Response Optimization Study in Subjects With Active Rheumatoid Arthritis (HERO)

Abbott1 个研究点 分布在 1 个国家目标入组 1,938 人开始时间: 2004年8月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
1,938
试验地点
1
主要终点
Patient reported outcomes, clinical response indicators.

研究概览

简要总结

The purpose of the study is to assess the efficacy of adalimumab in subjects with rheumatoid arthritis focusing on subject-reported outcomes and early response to treatment

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history.
  • •Subject, based on assessment of investigator, meets the definition of active RA

排除标准

  • •Subject considered by the investigator, for any reason, to be an unsuitable candidate for the study
  • •Female subject who is pregnant or breast-feeding or considering becoming pregnant

研究组 & 干预措施

未命名试验

干预措施: adalimumab (Drug)

结局指标

主要结局

Patient reported outcomes, clinical response indicators.

次要结局

  • Subject reported assessments of disease activity, physician reported assessments of disease activity, safety parameters, clinical response indicators.

研究者

发起方
Abbott
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Efficacy of HUMIRA in Subjects With Active... | 临床试验